Terms: = Endocrine gland cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Diagnosis
63 results:
1. CD133, CD47, and pd-l1 Expression in Ovarian High-grade Serous Carcinoma and Its Association with Metastatic Disease: A Cross-sectional Study.
Masadah R; Ikram D; Riadi R; Tangdiung Y; Nelwan BJ; Ghaznawie M; Rauf S; Faruk M
Asian Pac J Cancer Prev; 2024 Jan; 25(1):249-255. PubMed ID: 38285791
[TBL] [Abstract] [Full Text] [Related]
2. Therapeutic Potential of Targeting Transforming Growth Factor-beta (TGF-β) and Programmed Death-ligand 1 (pd-l1) in Pancreatic cancer.
Pourali G; Zafari N; Velayati M; Mehrabadi S; Maftooh M; Hassanian SM; Mobarhan MG; Ferns GA; Avan A; Khazaei M
Curr Drug Targets; 2023; 24(17):1335-1345. PubMed ID: 38053355
[TBL] [Abstract] [Full Text] [Related]
3. Expression of EGFR, pd-l1, and the mismatch repair proteins before and following therapy in malignant serous effusions with metastatic high-grade serous tubo-ovarian carcinoma.
Nikas IP; Park SY; Song MJ; Lee C; Ryu HS
Diagn Cytopathol; 2024 Feb; 52(2):69-75. PubMed ID: 37937321
[TBL] [Abstract] [Full Text] [Related]
4. Intrathyroid thymic carcinoma: A clinicopathological analysis of 22 cases.
Gao Y; Pan Y; Luo Y; Cheng R; Zhai Q
Ann Diagn Pathol; 2023 Dec; 67():152221. PubMed ID: 37925863
[TBL] [Abstract] [Full Text] [Related]
5. Necroptosis-related regulatory pattern and scoring system for predicting therapeutic efficacy and prognosis in ovarian cancer.
Lai H; Guo Y; Wu L; Yusufu A; Zhong Q; Liao Z; Ma J; Shi W; Yang G; Chen S
Cancer Rep (Hoboken); 2023 Oct; 6(10):e1893. PubMed ID: 37681751
[TBL] [Abstract] [Full Text] [Related]
6. [diagnosis and treatment of malignant mesothelioma of the tunica vaginalis testis: a series of 7 cases].
Huang KB; Cao Y; Yao K; Zhou FJ; Liu ZW; Li XD
Zhonghua Wai Ke Za Zhi; 2023 Sep; 61(9):812-817. PubMed ID: 37491176
[No Abstract] [Full Text] [Related]
7. Role of Immune Microenvironment in Pancreatic Ductal Adenocarcinoma: Could It Be Considered a Predictor of Prognosis?
De Simoni O; Dal Santo L; Scarpa M; Munari G; Spolverato YC; Scapinello A; Lonardi S; Soldà C; Bergamo F; Fantin A; Bardini R; Pilati P; Fassan M; Gruppo M
Curr Oncol; 2023 Jun; 30(6):5515-5528. PubMed ID: 37366900
[TBL] [Abstract] [Full Text] [Related]
8. The prognostic role of epidermal growth factor receptor mutation in completely resected ampullary adenocarcinoma.
Varol U; Cakır E; Aktas S; Altun ZS; Dilek FH; Butun O; Salman T; Unlu AGD; Alacacioglu A; Somali I
Pol J Pathol; 2023; 74(1):18-28. PubMed ID: 37306349
[TBL] [Abstract] [Full Text] [Related]
9. Mass Spectrometry-Based Proteomics of Epithelial Ovarian cancers: A Clinical Perspective.
Qian L; Sun R; Xue Z; Guo T
Mol Cell Proteomics; 2023 Jul; 22(7):100578. PubMed ID: 37209814
[TBL] [Abstract] [Full Text] [Related]
10. Low plasma pd-l1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer.
Fanale D; Brando C; Corsini LR; Cutaia S; Di Donna MC; Randazzo U; Filorizzo C; Lisanti C; Magrin L; Gurrera V; Romano R; Dimino A; Bazan Russo TD; Olive D; Vieni S; Pantuso G; Giordano A; Chiantera V; Russo A; Bazan V; Iovanna JL
BMC Cancer; 2023 May; 23(1):437. PubMed ID: 37179293
[TBL] [Abstract] [Full Text] [Related]
11. pd-l1 and MCL-1 markers and the relationship with prognostic characteristics of differentiated thyroid carcinoma.
Zantut-Wittmann DE; Barreto IS; Laus AC; Moreno DA; Moma CA; Maia FFR; Assumpção LVMD; Reis RM
Mol Cell Endocrinol; 2023 Jun; 570():111931. PubMed ID: 37072108
[TBL] [Abstract] [Full Text] [Related]
12. Anaplastic thyroid carcinoma: advances in molecular profiling and targeted therapy.
Jungels C; Pita JM; Costante G
Curr Opin Oncol; 2023 Jan; 35(1):1-9. PubMed ID: 36398690
[TBL] [Abstract] [Full Text] [Related]
13. Case report: Two pd-l1 positive unresectable advanced pancreatic carcinoma patients with microsatellite stability achieved R0 resection after PD-1 antibody plus chemotherapy as a successful downstaging therapy: A report of two cases.
Shang L; Li P; Fan J; Zhao C; Niu X; Bian Q; Yuan Z; Kong Y; Zhu T; Xu B; Dong J; Xiang H
Front Immunol; 2022; 13():946266. PubMed ID: 36203575
[TBL] [Abstract] [Full Text] [Related]
14. Immunohistochemical analysis of a panel of cancer stem cell markers and potential therapeutic markers in pancreatic ductal adenocarcinoma.
Ali SMA; Adnan Y; Ali SM; Ahmad Z; Chawla T; Farooqui HA
J Cancer Res Clin Oncol; 2023 Jun; 149(6):2279-2292. PubMed ID: 36066622
[TBL] [Abstract] [Full Text] [Related]
15. Stocky/Packed Pancreas: A Case of Focal Drug-Induced Acute Pancreatitis Mimicking cancer.
Di Serafino M; Ronza R; D'Auria D; Fiorentino R; Arundine D; De Leone A; Picascia S; Martino A; Crolla E; Campione S; Guida G; Molino C; Riccardi F; Romano L
Tomography; 2022 Aug; 8(4):2073-2082. PubMed ID: 36006072
[TBL] [Abstract] [Full Text] [Related]
16. A case of osteoclastic variant of anaplastic thyroid carcinoma: Diagnostic and prognostic marker studies by cytology.
Bantumilli S; Zhu LC; Sakthivel M; Dodd L
Diagn Cytopathol; 2022 Dec; 50(12):E357-E360. PubMed ID: 35929756
[TBL] [Abstract] [Full Text] [Related]
17. Targeting PD-1/pd-l1 axis as new horizon for ovarian cancer therapy.
Khatoon E; Parama D; Kumar A; Alqahtani MS; Abbas M; Girisa S; Sethi G; Kunnumakkara AB
Life Sci; 2022 Oct; 306():120827. PubMed ID: 35907493
[TBL] [Abstract] [Full Text] [Related]
18. Spatially resolved immune microenvironmental profiling for follicular thyroid carcinoma with minimal capsular invasion.
Saburi S; Tsujikawa T; Miyagawa-Hayashino A; Mitsuda J; Yoshimura K; Kimura A; Morimoto H; Ohmura G; Arai A; Ogi H; Konishi E; Itoh K; Sugino K; Hirano S
Mod Pathol; 2022 Jun; 35(6):721-727. PubMed ID: 34952946
[TBL] [Abstract] [Full Text] [Related]
19. Biomarkers of Central Nervous System Involvement from Epithelial Ovarian cancer.
Scotto G; Borella F; Turinetto M; Tuninetti V; Valsecchi AA; Giannone G; Cosma S; Benedetto C; Valabrega G
Cells; 2021 Dec; 10(12):. PubMed ID: 34943916
[TBL] [Abstract] [Full Text] [Related]
20. Prognostic Value of Tissue-Resident Memory T Cells and Tumor Microenvironmental Features in Resected Pancreatic Adenocarcinoma.
Başoğlu T; Akar KE; Bağcı P; Akgül Babacan N; Öztürk MA; Öztürk FE; Demircan NC; Arikan R; Akın Telli T; Ercelep Ö; Dane F; Yumuk PF
Balkan Med J; 2022 Jan; 39(1):12-20. PubMed ID: 34928235
[TBL] [Abstract] [Full Text] [Related]
[Next]
